Broadview Ventures

Relief Cardiovascular develops an innovative smart implant designed to monitor and modulate blood flow, aiming to reduce congestion in the heart and potentially improve outcomes for patients with congestive heart failure.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions in patients experiencing heart attacks. The company has created a controlled flow infusion system that utilizes a proprietary concept to measure microvascular resistance, allowing interventional cardiologists to assess the severity of microvascular obstruction. By comparing these measurements with post-procedure contrast-enhanced magnetic resonance imaging, CorFlow's technology aims to improve the diagnosis and treatment of microvascular obstruction, potentially reducing both short- and long-term complications for severe heart attack patients. Through its advancements, CorFlow is committed to addressing significant unmet medical needs in cardiology.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Puzzle Medical Devices develops innovative heart pump solutions to treat advanced heart failure. Its flagship product, ModulHeart, is a modular percutaneous device designed to reduce cardiac afterload and improve renal perfusion. The device's unique design enables safe percutaneous implantation, supporting both renal and cardiac function with low risk of complications. Puzzle Medical has successfully completed its first-in-human study, demonstrating improvements in cardiac and kidney function.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

Puzzle Medical Devices develops innovative heart pump solutions to treat advanced heart failure. Its flagship product, ModulHeart, is a modular percutaneous device designed to reduce cardiac afterload and improve renal perfusion. The device's unique design enables safe percutaneous implantation, supporting both renal and cardiac function with low risk of complications. Puzzle Medical has successfully completed its first-in-human study, demonstrating improvements in cardiac and kidney function.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, specializing in innovative solutions for patients with congestive heart failure. Founded in 2011, the company has developed the V-LAP, the first in-heart microcomputer designed to enhance treatment for heart failure patients by facilitating daily monitoring of left atrial pressure (LAP). This miniature wireless implant is a groundbreaking device that operates without batteries and can transmit data from deep within the body, offering a reliable means of detecting potential deterioration in heart failure. The V-LAP has been recognized as an effective predictor of heart failure worsening, thereby improving patients' quality of life and life expectancy. Vectorious is currently conducting clinical studies in various European countries, including Italy, Germany, and the UK, to obtain regulatory approval, with plans to initiate a clinical study in the United States.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Founded in 2012, Adient Medical specializes in developing absorbable medical devices. Its flagship product is an absorbable vascular filter designed for preventing pulmonary embolisms, aiming to enhance patient safety and reduce complications associated with traditional implants.

CellAegis Devices Inc. is a Toronto-based company that specializes in developing, manufacturing, and commercializing medical devices. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner to protect the heart during heart attacks and other cardiovascular procedures. This automated device is designed for use in various settings, including hospitals, ambulances, and at home. Additionally, the company provides the CRICtrac mobile app, which enables clinicians to offer patients self-administered chronic RIC therapy at home. CellAegis Devices serves a broad market across Canada and Europe, focusing on enhancing patient care through innovative medical technology.

Nido is a medical device manufacturer specializing in innovative solutions for cardiac procedures. The company is developing SEPIA, an advanced Epicardial Ablation Solution aimed at treating cardiac arrhythmias, particularly ventricular tachycardia. This novel platform allows for video-endoscopic trans-cardiac surgical repairs within the beating heart, which enhances the precision and effectiveness of interventions. Nido's device is designed to be inserted through small incisions in the chest and heart wall, facilitating minimally invasive surgeries while eliminating the need for cardiopulmonary bypass. This technology, developed from research at Boston Children's Hospital, underscores Nido's commitment to improving patient outcomes in cardiac care.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Founded in 2011, InfoBionic specializes in remote patient monitoring. Its flagship product, MoMe™, is a cloud-based SaaS service that wirelessly monitors patients, initially focusing on cardiac arrhythmia detection.

Apama Medical, Inc. is a medical device company that specializes in catheter ablation technology for the treatment of atrial fibrillation (AF). Founded in 2009 and based in Campbell, California, the company offers a radiofrequency balloon catheter system designed to enhance the effectiveness of ablation procedures. This innovative system integrates multi-electrode technology, allowing for the delivery of energy in a manner that combines the advantages of both point-by-point and balloon-based ablation techniques. The system features built-in digital cameras, LED lights, and sensing electrodes, which facilitate real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical operates in the rapidly growing electrophysiology market, aiming to improve the detection and treatment of heart rhythm disorders. Since October 2017, the company has been a subsidiary of Boston Scientific Corporation.

Founded in 2011, InfoBionic specializes in remote patient monitoring. Its flagship product, MoMe™, is a cloud-based SaaS service that wirelessly monitors patients, initially focusing on cardiac arrhythmia detection.

Vascular Graft Solutions Ltd. is an Israeli company founded in 2009, dedicated to developing innovative medical devices aimed at improving the outcomes of bypass surgeries and enhancing patients' quality of life. The company's flagship product, VEST, is specifically designed for use in Coronary Artery Bypass Grafting (CABG) procedures. It addresses the critical issue of vascular graft failure by mitigating disease progression in venous bypass grafts, thereby improving their long-term performance. In addition to VEST, Vascular Graft Solutions specializes in external stents and scaffolds for cardiac and vascular surgery, focusing on solutions that tackle the challenges associated with vein graft diseases, surgical revascularization, vascular reconstruction, and arteriovenous fistula procedures.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

Apama Medical, Inc. is a medical device company that specializes in catheter ablation technology for the treatment of atrial fibrillation (AF). Founded in 2009 and based in Campbell, California, the company offers a radiofrequency balloon catheter system designed to enhance the effectiveness of ablation procedures. This innovative system integrates multi-electrode technology, allowing for the delivery of energy in a manner that combines the advantages of both point-by-point and balloon-based ablation techniques. The system features built-in digital cameras, LED lights, and sensing electrodes, which facilitate real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical operates in the rapidly growing electrophysiology market, aiming to improve the detection and treatment of heart rhythm disorders. Since October 2017, the company has been a subsidiary of Boston Scientific Corporation.

Aggamin Pharmaceuticals, LLC is a biotechnology company established in 2010 and located in New York. The company focuses on developing and commercializing innovative therapies for vascular diseases, with a primary emphasis on preeclampsia, a serious condition affecting about 5% of pregnancies and imposing a significant financial burden on the U.S. healthcare system. Aggamin's lead product is an extracorporeal device designed to reduce harmful circulating proteins associated with preeclampsia, aiming to improve both maternal and fetal health. By restoring the angiogenic balance disrupted in this condition, the company's objective is to provide a safe, first-in-class treatment that alleviates maternal symptoms, extends pregnancy duration, and enhances outcomes for both mothers and newborns.

Coridea is an idea generator, technology incubator, and consulting firm specializing in the development of medical devices aimed at improving the lives of patients with cardiac, pulmonary, renal, and neuro conditions. Established in 2003, Coridea has successfully launched six startup companies, including Ardian and CHF Solutions, and has achieved significant milestones such as the high-profile acquisition of Ardian by Medtronic. The firm holds 65 U.S. patents, which have been licensed to various companies in the medical field, and has raised over $150 million in venture capital financing. Coridea is recognized for its innovative contributions to medical technology, notably the award-winning Symplicity® Catheter System™, which offers novel solutions to complex clinical problems. Through its focus on applying existing technologies to new medical challenges, Coridea aims to redefine the medical landscape and enhance patient care.

NuPulseCV, Inc. is a medical device company focused on developing innovative treatments for patients with heart failure. The company specializes in the iVAS intravascular ventricular assist system, an investigational device designed to provide a minimally invasive alternative to traditional medical therapies for advanced heart failure patients. This device aims to alleviate symptoms and improve the quality of life for individuals who are not responding to standard treatments, allowing for potential discharge from the hospital and a return to daily activities. Founded in 2010 and based in Raleigh, North Carolina, NuPulseCV boasts a team with extensive expertise in clinical, engineering, and life sciences. The company collaborates strategically with a leading firm in the heart failure sector to enhance the development and evaluation of its technologies through clinical trials.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

CellAegis Devices Inc. is a Toronto-based company that specializes in developing, manufacturing, and commercializing medical devices. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner to protect the heart during heart attacks and other cardiovascular procedures. This automated device is designed for use in various settings, including hospitals, ambulances, and at home. Additionally, the company provides the CRICtrac mobile app, which enables clinicians to offer patients self-administered chronic RIC therapy at home. CellAegis Devices serves a broad market across Canada and Europe, focusing on enhancing patient care through innovative medical technology.

Intravascular Imaging is a company focused on advancing cardiovascular imaging technologies to enhance the early detection of coronary artery disease and improve post-interventional therapeutic viability. Established through a collaboration between Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, the company develops innovative techniques for detecting and stratifying atherosclerotic plaques in human arteries. Its offerings include prototype devices, software, and systems aimed at reducing hospital readmissions following percutaneous coronary interventions. By providing a comprehensive catheter-based approach, Intravascular Imaging enables healthcare professionals to identify high-risk plaques, ultimately improving patient outcomes in cardiovascular care.